IL303216A - A preparation for the treatment of hypothyroidism - Google Patents

A preparation for the treatment of hypothyroidism

Info

Publication number
IL303216A
IL303216A IL303216A IL30321623A IL303216A IL 303216 A IL303216 A IL 303216A IL 303216 A IL303216 A IL 303216A IL 30321623 A IL30321623 A IL 30321623A IL 303216 A IL303216 A IL 303216A
Authority
IL
Israel
Prior art keywords
pth
composition
snac
protease inhibitor
optionally
Prior art date
Application number
IL303216A
Other languages
English (en)
Hebrew (he)
Inventor
Burshtein Gregory
Rothner Ariel
M Schwartz Phillip
GALITZER Hillel
Original Assignee
Entera Bio Ltd
Burshtein Gregory
Rothner Ariel
M Schwartz Phillip
GALITZER Hillel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entera Bio Ltd, Burshtein Gregory, Rothner Ariel, M Schwartz Phillip, GALITZER Hillel filed Critical Entera Bio Ltd
Publication of IL303216A publication Critical patent/IL303216A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL303216A 2015-02-09 2016-02-09 A preparation for the treatment of hypothyroidism IL303216A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562113638P 2015-02-09 2015-02-09
US201562113619P 2015-02-09 2015-02-09
US201562113600P 2015-02-09 2015-02-09
US201562113604P 2015-02-09 2015-02-09
US201562113625P 2015-02-09 2015-02-09
US201562113629P 2015-02-09 2015-02-09
US201562113673P 2015-02-09 2015-02-09
PCT/IL2016/050151 WO2016128970A1 (en) 2015-02-09 2016-02-09 Treatment of hypoparathyroidism

Publications (1)

Publication Number Publication Date
IL303216A true IL303216A (en) 2023-07-01

Family

ID=56614456

Family Applications (7)

Application Number Title Priority Date Filing Date
IL303216A IL303216A (en) 2015-02-09 2016-02-09 A preparation for the treatment of hypothyroidism
IL253802A IL253802B (en) 2015-02-09 2016-02-09 Treatment of osteoporosis
IL292218A IL292218B2 (en) 2015-02-09 2016-02-09 Formulations for oral administration of active agents with controlled absorption profile
IL292417A IL292417B2 (en) 2015-02-09 2016-02-09 Treatment of osteoporosis
IL283258A IL283258B2 (en) 2015-02-09 2016-02-09 A preparation for the treatment of hypothyroidism
IL253803A IL253803B (en) 2015-02-09 2017-08-02 A preparation for the treatment of hypothyroidism
IL253804A IL253804B (en) 2015-02-09 2017-08-02 Formulations for oral administration of active agents with controlled absorption profile

Family Applications After (6)

Application Number Title Priority Date Filing Date
IL253802A IL253802B (en) 2015-02-09 2016-02-09 Treatment of osteoporosis
IL292218A IL292218B2 (en) 2015-02-09 2016-02-09 Formulations for oral administration of active agents with controlled absorption profile
IL292417A IL292417B2 (en) 2015-02-09 2016-02-09 Treatment of osteoporosis
IL283258A IL283258B2 (en) 2015-02-09 2016-02-09 A preparation for the treatment of hypothyroidism
IL253803A IL253803B (en) 2015-02-09 2017-08-02 A preparation for the treatment of hypothyroidism
IL253804A IL253804B (en) 2015-02-09 2017-08-02 Formulations for oral administration of active agents with controlled absorption profile

Country Status (9)

Country Link
US (8) US20180028622A1 (cg-RX-API-DMAC7.html)
EP (5) EP3256153A4 (cg-RX-API-DMAC7.html)
JP (6) JP6925969B2 (cg-RX-API-DMAC7.html)
CN (5) CN107427481A (cg-RX-API-DMAC7.html)
CA (3) CA3011654A1 (cg-RX-API-DMAC7.html)
HK (5) HK1247843A1 (cg-RX-API-DMAC7.html)
IL (7) IL303216A (cg-RX-API-DMAC7.html)
MX (2) MX2017010220A (cg-RX-API-DMAC7.html)
WO (5) WO2016128970A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
MY161450A (en) 2011-04-12 2017-04-14 Novo Nordisk As Double-acylated glp-1 derivatives
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
PL2991671T3 (pl) 2013-05-02 2019-01-31 Novo Nordisk As Doustne dawkowanie związków glp-1
WO2016128970A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of hypoparathyroidism
EP3500291A4 (en) * 2016-08-17 2020-03-11 Entera Bio Ltd. FORMULA FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
JP6898518B2 (ja) * 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
JP7610410B2 (ja) * 2019-03-08 2025-01-08 アニヤ バイオファーム インク． 副甲状腺ホルモンアナログの経口製剤および治療
EP4025240B1 (en) * 2019-09-03 2024-10-30 Amgen Inc. Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
CN114306249A (zh) * 2020-09-28 2022-04-12 深圳翰宇药业股份有限公司 一种特立帕肽冻干药物组合物及其制备方法
US12251208B2 (en) * 2020-11-30 2025-03-18 International Business Machines Corporation Time controlled medication
CN114288388B (zh) * 2022-01-25 2023-11-03 华中科技大学同济医学院附属协和医院 网膜素在制备炎症性肠病治疗药物中的应用
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
KR20240145523A (ko) * 2022-02-24 2024-10-07 엔테라 바이오 리미티드 글루카곤 유사 펩타이드-2의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
CN119072329A (zh) * 2022-02-24 2024-12-03 安提拉生物有限公司 包含酸中和聚合物用于口服甲状旁腺激素的制剂
CN119031930A (zh) * 2022-02-24 2024-11-26 安提拉生物有限公司 包含酸中和聚合物用于口服胰高血糖素样肽-1及其类似物的制剂
EP4482507A1 (en) * 2022-02-24 2025-01-01 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of active agents
WO2023161938A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide
WO2023161935A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone
WO2025046590A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations for oral administration of active agents
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents
WO2025146144A1 (zh) * 2024-01-05 2025-07-10 成都国为生物医药有限公司 一种地非法林的口服药物组合物
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) * 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
CN1162917A (zh) * 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物，用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) * 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
EP0943336A1 (en) 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
HUP0003349A3 (en) 1997-05-14 2001-12-28 Aventis Pharmaceuticals Inc Co Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
WO2000050386A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
JP2004501057A (ja) 1999-11-05 2004-01-15 エミスフェアー・テクノロジーズ・インク フェニルアミンカルボン酸化合物及び活性剤を送達するための組成物
CN1437483A (zh) * 1999-12-28 2003-08-20 味之素株式会社 口服给药用糖尿病药物制剂
IL159714A0 (en) * 2001-08-17 2004-06-20 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
WO2003045306A2 (en) 2001-11-13 2003-06-05 Emisphere Technologies, Inc. Phenoxy amine compounds and compositions for delivering active agents
AU2002352974A1 (en) 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
CN1606434A (zh) 2001-12-19 2005-04-13 株式会社三和化学研究所 控制释放成型品
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TWI307279B (en) * 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
EP1643978A1 (en) 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
WO2006055928A2 (en) 2004-11-19 2006-05-26 Smithkline Beecham Corporation Pharmaceutical product
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
EP1843755B1 (en) * 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
KR101432313B1 (ko) 2005-11-17 2014-08-20 노파르티스 아게 약제학적 조성물
US20070178155A1 (en) * 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2538254T3 (es) 2006-04-18 2015-06-18 Emisphere Technologies, Inc. Agentes de administración de dialquil éter
KR101428826B1 (ko) * 2006-12-12 2014-08-08 가부시키가이샤 호리바 에스텍 유량 비율 제어 장치
JP2010523555A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド 「経口医薬組成物」
EP2152244B1 (en) * 2007-04-26 2015-12-02 Technion Research & Development Foundation Ltd. Oral administration of proteins and peptides
WO2009036084A2 (en) * 2007-09-11 2009-03-19 Orahealth Corporation Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
NZ591497A (en) * 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
EP2558106A1 (en) * 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
PT2651398T (pt) * 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
US20130224300A1 (en) 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
WO2016128970A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of hypoparathyroidism
EP3500291A4 (en) 2016-08-17 2020-03-11 Entera Bio Ltd. FORMULA FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Also Published As

Publication number Publication date
EP3256153A1 (en) 2017-12-20
EP3256149A1 (en) 2017-12-20
JP2018504444A (ja) 2018-02-15
JP2021176913A (ja) 2021-11-11
WO2016128972A1 (en) 2016-08-18
EP3256152A4 (en) 2018-11-14
JP6925970B2 (ja) 2021-08-25
CN113713090B (zh) 2023-06-02
IL292417B1 (en) 2024-08-01
EP3256114A4 (en) 2018-11-21
CN114949185A (zh) 2022-08-30
IL253804B (en) 2022-05-01
US20200138913A1 (en) 2020-05-07
IL253802A0 (en) 2017-09-28
EP3256113A4 (en) 2018-11-14
MX2022014313A (es) 2022-12-07
WO2016128974A1 (en) 2016-08-18
CN113694190B (zh) 2024-05-07
CA2975710A1 (en) 2016-08-18
MX2017010220A (es) 2018-02-21
US20180028622A1 (en) 2018-02-01
CA2975676A1 (en) 2016-08-18
US12076373B2 (en) 2024-09-03
US20180050096A1 (en) 2018-02-22
IL292218B2 (en) 2024-10-01
JP2023055902A (ja) 2023-04-18
IL253803A0 (en) 2017-09-28
US20180021272A1 (en) 2018-01-25
CN107427481A (zh) 2017-12-01
CA2975578A1 (en) 2016-08-18
CN113694190A (zh) 2021-11-26
IL253804A0 (en) 2017-09-28
JP2021176914A (ja) 2021-11-11
IL292417B2 (en) 2024-12-01
WO2016128973A1 (en) 2016-08-18
CA3011657A1 (en) 2016-08-18
IL283258B2 (en) 2023-11-01
CA2975710C (en) 2023-08-08
BR112017017112A2 (pt) 2018-04-03
WO2016128970A1 (en) 2016-08-18
IL292218B1 (en) 2024-06-01
CN113730556A (zh) 2021-12-03
EP3256113B1 (en) 2025-04-02
JP7275207B2 (ja) 2023-05-17
WO2016128971A1 (en) 2016-08-18
US20240398904A1 (en) 2024-12-05
EP3256114A1 (en) 2017-12-20
IL283258A (en) 2021-07-29
CN113713090A (zh) 2021-11-30
JP2023100920A (ja) 2023-07-19
US20240181020A1 (en) 2024-06-06
US20180036234A1 (en) 2018-02-08
IL292218A (en) 2022-06-01
HK1247823A1 (zh) 2018-10-05
JP2018504445A (ja) 2018-02-15
US10583177B2 (en) 2020-03-10
IL253802B (en) 2022-06-01
HK1247843A1 (zh) 2018-10-05
JP7775239B2 (ja) 2025-11-25
IL283258B1 (en) 2023-07-01
IL292417A (en) 2022-06-01
CA3011654A1 (en) 2016-08-18
EP3256152A1 (en) 2017-12-20
EP3256149A4 (en) 2019-08-14
HK1247835A1 (zh) 2018-10-05
EP3256113A1 (en) 2017-12-20
HK1247838A1 (zh) 2018-10-05
EP3256153A4 (en) 2018-11-21
IL253803B (en) 2021-06-30
HK1247822A1 (zh) 2018-10-05
US20180036382A1 (en) 2018-02-08
JP6925969B2 (ja) 2021-08-25

Similar Documents

Publication Publication Date Title
US20240181020A1 (en) Treatment of hypoparathyroidism
US20240415936A1 (en) Formulations for oral administration of active agents
CA2975578C (en) Treatment of hypoparathyroidism
CA3011657C (en) Formulations for oral administration of active agents